M
Mark C. Scholz
Researcher at University of California, Los Angeles
Publications - 38
Citations - 4362
Mark C. Scholz is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Prostate cancer & Enzalutamide. The author has an hindex of 12, co-authored 37 publications receiving 3940 citations.
Papers
More filters
Journal ArticleDOI
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. de Bono,Christopher J. Logothetis,Arturo Molina,Karim Fizazi,Scott North,Luis Chu,Kim N. Chi,Robert Jones,Oscar B. Goodman,Fred Saad,John Staffurth,Paul N. Mainwaring,S. J. Harland,Thomas W. Flaig,Thomas E. Hutson,Tina Cheng,Helen Patterson,John D. Hainsworth,Charles J. Ryan,Cora N. Sternberg,Susan Ellard,Aude Flechon,Mansoor N. Saleh,Mark C. Scholz,Eleni Efstathiou,Andrea Zivi,Diletta Bianchini,Yohann Loriot,Nicole Chieffo,Thian Kheoh,Christopher M. Haqq,Howard I. Scher +31 more
TL;DR: The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy.
Journal ArticleDOI
Re: recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil
Mark C. Scholz,Stephen B. Strum +1 more
Journal ArticleDOI
Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy.
TL;DR: It is hypothesized that prostate cancer patients who achieve and maintain an undetectable prostate-specific antigen (UD-PSA) on androgen deprivation therapy (ADT) have a predominantly androgen-dependent cancer cell population sensitive to apoptosis that allows for a prolonged time off ADT.
Journal ArticleDOI
Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer
Celestia S. Higano,Andrew J. Armstrong,A. Oliver Sartor,Nicholas J. Vogelzang,Philip W. Kantoff,David G. McLeod,Christopher Michael Pieczonka,David F. Penson,Neal D. Shore,Jeffrey L. Vacirca,Raoul S. Concepcion,Ronald F. Tutrone,Luke T. Nordquist,David I. Quinn,Vahan Kassabian,Mark C. Scholz,Matthew Harmon,Robert Claude Tyler,Nancy N. Chang,Hong Tang,Matthew R. Cooperberg +20 more
TL;DR: The large registry, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (PROCEED) evaluated sipuleucel‐T immunotherapy for asymptomatic/minimally symptomatic metastatic metastatic castration‐resistant prostate cancer (mCRPC).
Journal ArticleDOI
Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone
Mark C. Scholz,Robert I. Jennrich,Stephen B. Strum,Stanley A. Brosman,Henry Johnson,Richard Y. Lam +5 more
TL;DR: Ketoconazole can induce prolonged responses, occasionally lasting for years, and long responses are more likely to occur in men initiating HDK earlier in the course of disease before the cancer burden becomes excessive.